AUS
NZ
UK
CA
USA
IND
Highlights:
- Strategic Partnership: Trellus Health will integrate its Trellus Elevate™ program into a Patient Support Program (PSP) for eligible patients prescribed a Johnson & Johnson therapy for IBD.
- Financial Terms: Trellus Health will receive an upfront licensing fee and a fixed monthly management fee for the one-year pilot program.
- Patient-Centered Approach: The initiative aims to enhance patient outcomes by addressing both the emotional and physical challenges of managing IBD.
Trellus Health plc (LSE:TRLS), a healthcare company specializing in digital health solutions for chronic conditions, has announced a new collaboration with Johnson & Johnson Health Care Systems Inc. The agreement will pilot the Trellus Elevate™ platform in the US to support patients with moderately to severely active inflammatory bowel disease (IBD).
Trellus Elevate™: A Comprehensive Support Platform
The Trellus Elevate™ platform combines data analytics with personalized, evidence-based resilience programs to support individuals with complex chronic conditions. By incorporating this platform into Johnson & Johnson’s PSP, the program aims to provide eligible IBD patients with tailored tools and resources to manage their condition alongside prescribed therapies.
The platform focuses on empowering patients to stay engaged, adhere to treatment plans, and take control of their health journey, ultimately improving treatment outcomes.
Partnership Goals
The one-year pilot will assess the potential of Trellus Elevate™ to support patients using Johnson & Johnson therapies for IBD. The collaboration underscores the growing trend of integrating digital health solutions with pharmaceutical therapies to deliver value-based care.
